CTNNB1 and non-small cell lung carcinoma: This raises questions about the potential benefit of combining EGFR TKIs with β-catenin inhibitors to enhance clinical outcomes in EGFR-mutant NSCLC.21 This is in contrast to previous studies that focused on the role of CTNNB1 as possible resistance mechanism or lacked sufficient clinical data.9,11-18